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Background:  We have found that cilostazol may have beneficial effects on endothelial progenitor cells (EPCs) in vitro and can provide 
vasculo-angiogenic effect in vivo. This study, for the first time, investigated the vasculo-angiogenic effects of cilostazol on EPCs and flow-
mediated dilatation (FMD) in patients with high risk for cardiovascular disease (CVD).
methods:  Seventy-one eligible patients (37 received 200 mg cilostazol and 34 took placebo per day for 12 weeks) who had high-risk 
profile for CVD but without pre-existing CVD were consecutively enrolled in this double-blind and placebo-controlled study. Circulating 
number and EPCs and in vitro functions were assessed, and plasma biomarkers were measured by enzyme-linked immunosorbent assay. 
FMD in response to reactive hyperemia was measured in the left brachial artery by using a high-resolution ultrasound machine equipped 
with a 7.5 MHz linear array probe.
results:  The background characteristics and parameters in cilostazol treatment group and placebo group were similar and well matched. 
Cilostazol, but not placebo, significantly increased circulating EPCs (KDR+CD34+) count [percentage changes: 149.0 (67.9-497.8) vs. 71.9 
(-31.8-236.5)%, P=0.024] without influence on apoptotic endothelial cells. Cilostazol also improved triglyceride and high density lipoprotein 
levels (-9.9 ± 6.1 vs. 17.7 ± 6.1%, P=0.002; 8.7 ± 3.0 vs. -2.4 ± 2.1%, P=0.003, respectively). Plasma levels of vascular endothelial growth 
factor (VEGF)-A165 and FMD were significantly increased [72.5 (32.9-120.4) vs. -5.8 (-46.0-57.6)%, P=0.001; 232.8 ± 83.1 vs. -46.9 ± 
21.5%, P=0.003, respectively], whereas stromal cell-derived factor-1α or adiponectin was not significantly affected, in participants treated 
with cilostazol. Changes of plasma triglyceride levels were inversely correlated to the changes of VEGF-A165 and FMD significantly (R=-
0.278, P=0.035; R=-0.27, P=0.04, respectively).
Conclusion:  Cilostazol has significantly beneficial effects on mobilization of EPCs with better endothelium-dependent function partly 
mediated by modifying some metabolic and angiogenic markers in patients with high-risk profile for CVD.
